Literature DB >> 22836782

Patients' motives for participating in active post-marketing surveillance.

Linda Härmark1, Miguel Lie-Kwie, Lisette Berm, Han de Gier, Kees van Grootheest.   

Abstract

PURPOSE: Web-based intensive monitoring is a method to actively collect information about adverse drug reactions (ADRs) using patients as a source of information. To date, little is known about patients' motivation to participate in this kind of active post-marketing surveillance (PMS). Increased insight in this matter can help us to better understand and interpret patient reported information, and it can be used for developing and improving patient-based pharmacovigilance tools. The aim of this study is to gain insight into patients' motives for participating in active PMS and investigate their experiences with such a system.
METHOD: A mixed model approach combining qualitative and quantitative research methods was used. For both parts, patients participating in a web-based intensive monitoring study about the safety of anti-diabetic drugs (excluding insulins) were used. A questionnaire was developed based on the results from qualitative interviews. The data collected through the questionnaires was analysed with descriptive statistics. Relations between patient characteristics and motives were analysed using a t-test or a Chi-squared test.
RESULTS: 1332 (54.6%) patients responded to the questionnaire. The main motive for participation was altruism. Often experiencing ADRs or negative experiences with drugs were not important motives. The patient's gender played a role in the different motives for participation. For men, potential future personal benefit from the results was more important than for women. The overall opinion about the system was positive.
CONCLUSION: The knowledge that patients participate in this kind of research from an altruistic point of view may strengthen patient involvement in pharmacovigilance.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836782     DOI: 10.1002/pds.3327

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

1.  Time course, outcome and management of adverse drug reactions associated with metformin from patient's perspective: a prospective, observational cohort study in the Netherlands.

Authors:  Loek de Jong; Linda Härmark; Eugène van Puijenbroek
Journal:  Eur J Clin Pharmacol       Date:  2016-02-11       Impact factor: 2.953

Review 2.  Sex Differences in Human and Animal Toxicology.

Authors:  Michael Gochfeld
Journal:  Toxicol Pathol       Date:  2016-11-28       Impact factor: 1.902

Review 3.  Factors affecting patient reporting of adverse drug reactions: a systematic review.

Authors:  Rania Al Dweik; Dawn Stacey; Dafna Kohen; Sanni Yaya
Journal:  Br J Clin Pharmacol       Date:  2016-11-25       Impact factor: 4.335

4.  Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?

Authors:  F Kheloufi; A Default; F Rouby; D Laugier-Castellan; M Boyer; B Rodrigues; J Ponte-Astoul; M J Jean-Pastor; O Blin; J Micallef
Journal:  Eur J Clin Pharmacol       Date:  2017-04-08       Impact factor: 2.953

5.  Experiences with the use of varenicline in daily practice in the Netherlands: a prospective, observational cohort study.

Authors:  Ingrid Oosterhuis; Linda Härmark; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

6.  Consumers' adverse drug event reporting via community pharmacists: three stakeholder perception.

Authors:  Tanattha Kitisopee; Jirunya Assanee; Bernard A Sorofman; Suntaree Watcharadmrongkun
Journal:  J Pharm Policy Pract       Date:  2022-03-14

7.  Willingness to participate in, support or carry out scientific studies for benefit assessment of available medical interventions: A stakeholder survey.

Authors:  Julia Stadelmaier; Joerg J Meerpohl; Ingrid Toews
Journal:  PLoS One       Date:  2022-08-12       Impact factor: 3.752

Review 8.  Patient Participation and the Use of Ehealth Tools for Pharmacoviligance.

Authors:  Joëlle Berrewaerts; Laure Delbecque; Pierre Orban; Martin Desseilles
Journal:  Front Pharmacol       Date:  2016-04-11       Impact factor: 5.810

9.  vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.

Authors:  Tomas Bergvall; G Niklas Norén; Marie Lindquist
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.